Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kragballe, K.
102  Ergebnisse:
Personensuche X
?
1

Quality of life and patient benefit following transition fr..:

Augustin, M. ; Blome, C. ; Paul, C....
Journal of the European Academy of Dermatology and Venereology.  31 (2016)  2 - p. 294-303 , 2016
Link: https://doi.org/10.1111/..
 
?
2

Tumour necrosis factor-α plays a significant role in the Al..:

Vinter, H. ; Kragballe, K. ; Steiniche, T....
British Journal of Dermatology.  174 (2016)  5 - p. 1011-1021 , 2016
Link: https://doi.org/10.1111/..
 
?
3

One‐year safety and efficacy of ustekinumab and results of ..:

Reich, K. ; Puig, L. ; Paul, C....
British Journal of Dermatology.  170 (2014)  2 - p. 435-444 , 2014
Link: https://doi.org/10.1111/..
 
?
4

Aldara®-induced skin inflammation: studies of patients with..:

Vinter, H. ; Iversen, L. ; Steiniche, T...
British Journal of Dermatology.  172 (2014)  2 - p. 345-353 , 2014
Link: https://doi.org/10.1111/..
 
?
5

Transition to ustekinumab in patients with moderate-to-seve..:

Paul, C. ; Puig, L. ; Kragballe, K....
British Journal of Dermatology.  170 (2014)  2 - p. 425-434 , 2014
Link: https://doi.org/10.1111/..
 
?
6

Pooled safety analysis of calcipotriol plus betamethasone d..:

Kragballe, K. ; van de Kerkhof, P.
Journal of the European Academy of Dermatology and Venereology.  28 (2014)  s2 - p. 10-21 , 2014
Link: https://doi.org/10.1111/..
 
?
7

The expression of dual-specificity phosphatase 1 mRNA is do..:

Kjellerup, R.B. ; Johansen, C. ; Kragballe, K..
British Journal of Dermatology.  168 (2013)  2 - p. 339-345 , 2013
Link: https://doi.org/10.1111/..
 
?
8

Barriers to the prescription of systemic therapies for mode..:

Nast, A. ; Mrowietz, U. ; Kragballe, K....
Archives of Dermatological Research.  305 (2013)  10 - p. 899-907 , 2013
Link: https://doi.org/10.1007/..
 
?
9

A consensus report on appropriate treatment optimization an..:

Mrowietz, U. ; de Jong, E.M.G.J. ; Kragballe, K....
Journal of the European Academy of Dermatology and Venereology.  28 (2013)  4 - p. 438-453 , 2013
Link: https://doi.org/10.1111/..
 
?
10

Effet à long terme de l'ustekinumab sur la qualité de vie c..:

Reich, K. ; Puig, L. ; Luger, T....
Annales de Dermatologie et de Vénéréologie.  139 (2012)  12 - p. B165-B166 , 2012
Link: https://doi.org/10.1016/..
 
?
11

Tolérance et efficacité à long terme d'ustekinumab chez les..:

Paul, C. ; Puig, L. ; Luger, T....
Annales de Dermatologie et de Vénéréologie.  139 (2012)  12 - p. B164-B165 , 2012
Link: https://doi.org/10.1016/..
 
?
12

An assessment of adalimumab efficacy in three Phase III cli..:

Mrowietz, U. ; Kragballe, K. ; Reich, K....
British Journal of Dermatology.  168 (2012)  2 - p. 374-380 , 2012
Link: https://doi.org/10.1111/..
 
?
13

PSS28 Long-Term Improvement in Patient-Reported Outcomes Af..:

Reich, K. ; Puig, L. ; Luger, T....
Value in Health.  15 (2012)  7 - p. A573 , 2012
Link: https://doi.org/10.1016/..
 
?
14

Dimethylfumarate inhibits MIF-induced proliferation of kera..:

Gesser, B. ; Rasmussen, M. K. ; Raaby, L....
Inflammation Research.  60 (2011)  7 - p. 643-653 , 2011
Link: https://doi.org/10.1007/..
 
?
15

PSS45 Treatment Patterns, Treatment Satisfaction, Disease S..:

Ragnarson tennvall, G. ; Hjortsberg, C. ; Bjarnason, A....
Value in Health.  14 (2011)  7 - p. A510 , 2011
Link: https://doi.org/10.1016/..
 
1-15